Exelixis
EXEL
#1305
Rank
โ‚น1.632 T
Marketcap
โ‚น6,589
Share price
4.82%
Change (1 day)
92.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น302.96

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น313.33. In 2025 the company made an earnings per share (EPS) of โ‚น274.41.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น302.9610.4%
2025โ‚น274.41
2023โ‚น62.0314.61%
2022โ‚น54.12-22.97%
2021โ‚น70.26100%
2020โ‚น35.13-65.09%
2019โ‚น100.65-53.91%
2018โ‚น218.38333.96%
2017โ‚น50.32-260.61%
2016-โ‚น31.33-58.75%
2015-โ‚น75.96-42.45%
2014-โ‚น131.985.3%
2013-โ‚น125.33

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น829.27 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น72.16-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,540 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น180.68-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น120.16-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น431.07 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น303.62-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น1,350-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น79.76-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA